Latest Amgen Stories
Five Phase 3 Studies With Evolocumab (AMG 145) to be Featured in Late-Breaking and Clinical Research Presentations - Data Form the Basis of Global Filing Plan THOUSAND OAKS, Calif., March 24,
SAN DIEGO, March 20, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, March 19, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts'
Study Meets Primary Endpoint of LDL Cholesterol Reduction THOUSAND OAKS, Calif., March 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 TESLA (Trial Evaluating
Data Showed Tumor Shrinkage in Both Injected and Metastasized Tumors THOUSAND OAKS, Calif., March 14, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced findings from a pre-specified
ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Epoetin Alfa Market, 2009-2018” to its store. Dallas, TX (PRWEB) March
WHIPPANY, N.J., THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 11, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
THOUSAND OAKS, Calif., March 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the second quarter of 2014.
THOUSAND OAKS, Calif., March 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 34(th) Annual Healthcare Conference at 2:10 p.m. ET on Monday, Mar.
MarketOptimizer.org offers “PharmaPoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022” research report in its store. Dallas, TX (PRWEB)
- a meat pie that is usually eaten at Christmas in Quebec